Enhancing adherence to anticoagulant therapy in atrial fibrillation
Understanding atrial fibrillation and NOAC therapy Atrial Fibrillation (AF), a prevalent cardiac condition affecting approximately 2.3 million Americans, is characterized by an irregular and often rapid heart rate. This condition significantly increases the risk of stroke, heart failure, and other heart-related complications. The advent of Non-Vitamin K Oral Anticoagulants (NOACs): dabigatran, rivaroxaban, apixaban, and edoxaban…